Radware (RDWR): Evaluating Valuation After New Cloud Security Centers Expand Global Coverage

If you have been following Radware (RDWR), there is a fresh catalyst to pay attention to. The company just announced the launch of two new cloud security centers in Tel Aviv and Bogota, ramping up its global network to more than 50 locations. This expansion not only increases Radware’s attack mitigation capacity but also demonstrates their commitment to staying ahead of new threats, given the major surge in web-based and application-layer attacks highlighted in their recent 2025 Global Threat Analysis.

This latest move follows recent security center additions in India, Kenya, and Peru. Over the past year, Radware’s stock has climbed 25%, handily outpacing more modest results from previous years. With annual revenues growing 7%, the company appears to be experiencing positive momentum, supported by industry recognition from groups like Forrester and Gartner for their innovative cybersecurity solutions.

With this momentum and ongoing expansion, some investors may be considering whether Radware is at an attractive entry point or if the market has already factored in optimistic expectations for future growth.

Advertisement

Price-to-Earnings of 77x: Is it justified?

Radware is currently valued at a price-to-earnings (P/E) ratio of 77 times, a figure that marks it as significantly more expensive than both the US software industry average of 35.8x and its peer average of 25.1x. On a pure valuation basis, this suggests a premium is being paid for Radware shares compared to sector and peer benchmarks.

The P/E ratio reflects how much investors are willing to pay now for each dollar of future earnings. For software companies, a higher ratio sometimes signals expectations for exceptional growth, innovation, or sustainable profits. However, a high multiple also heightens pressure for Radware to maintain or accelerate profit growth to justify its valuation.

With recent profitability and positive momentum, investors might see some rationale for the premium. Still, the multiple indicates that the market could be overpricing expected earnings relative to what peers command, especially given the company's historic earnings performance.

Result: Fair Value of $21.57 (OVERVALUED)

See our latest analysis for Radware.

However, slowing net income growth or a failure to deliver on analyst price targets could challenge Radware’s valuation premium in the future.

Find out about the key risks to this Radware narrative.

Another View: Our DCF Model's Perspective

While the market is pricing Radware high relative to other software companies, our SWS DCF model also judges the shares to be overvalued at this time. Could both methods be overlooking something? Or is this a warning signal?

Look into how the SWS DCF model arrives at its fair value.
RDWR Discounted Cash Flow as at Sep 2025
RDWR Discounted Cash Flow as at Sep 2025
Stay updated when valuation signals shift by adding Radware to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Radware Narrative

If you have a different take or want to investigate the data further, you can easily build and share your unique insights in just a few minutes with our tools. Do it your way

A great starting point for your Radware research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for More Smart Investment Opportunities?

Don't hold back your portfolio potential. Open the door to a world of unique investment ideas handpicked for forward-thinkers, only on Simply Wall Street.

  • Tap into market disruptors offering strong financials by checking out penny stocks with strong financials and discover what could be next in powerful small-cap growth stories.
  • Uncover savings with stocks currently undervalued by cash flow metrics using undervalued stocks based on cash flows so you never miss a bargain others might overlook.
  • Put yourself at the cutting edge of technology by spotting tomorrow's breakthroughs with quantum computing stocks and gain insight into companies shaping the quantum revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Kshitija Bhandaru

Kshitija Bhandaru

Kshitija (or Keisha) Bhandaru is an Equity Analyst at Simply Wall St and has over 6 years of experience in the finance industry and describes herself as a lifelong learner driven by her intellectual curiosity. She previously worked with Market Realist for 5 years as an Equity Analyst.

About NasdaqGS:RDWR

Radware

Develops, manufactures, and markets cyber security and application delivery solutions for cloud, on-premises, and software defined data centers.

Flawless balance sheet with solid track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
67 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0